CA2409355A1 - Composes neuroprotecteurs et anti-proliferatifs - Google Patents

Composes neuroprotecteurs et anti-proliferatifs Download PDF

Info

Publication number
CA2409355A1
CA2409355A1 CA002409355A CA2409355A CA2409355A1 CA 2409355 A1 CA2409355 A1 CA 2409355A1 CA 002409355 A CA002409355 A CA 002409355A CA 2409355 A CA2409355 A CA 2409355A CA 2409355 A1 CA2409355 A1 CA 2409355A1
Authority
CA
Canada
Prior art keywords
substituted
compound
mmol
lower alkyl
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002409355A
Other languages
English (en)
Inventor
John Gillard
Alex Fallis
James B. Jaquith
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aegera Therapeutics Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CA002308994A external-priority patent/CA2308994A1/fr
Application filed by Individual filed Critical Individual
Priority to CA002409355A priority Critical patent/CA2409355A1/fr
Publication of CA2409355A1 publication Critical patent/CA2409355A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des dérivés pyrrolo-.szlig.-carboline de substitution, la substitution de cycles et des dérivés structuraux de 3-(1<i>H</i>-indol-3-yl)-1<i>H</i>-pyrrole-2,5-dione de formules (I-III), utiles comme composés neuroprotecteurs et anti-prolifératifs. L'invention concerne également des procédés de préparation de ces composés, des profils biologiques sélectionnés et des utilisations de ces composés dans le traitement de différentes maladies neurodégénératives et inflammatoires du système nerveux central et dans le traitement de différents troubles prolifératifs caractérisés par la perte de régulation de la croissance ou de la différenciation cellulaire, dont, entre autres, les cancers et les inflammations.
CA002409355A 2000-05-19 2001-05-18 Composes neuroprotecteurs et anti-proliferatifs Abandoned CA2409355A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA002409355A CA2409355A1 (fr) 2000-05-19 2001-05-18 Composes neuroprotecteurs et anti-proliferatifs

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CA002308994A CA2308994A1 (fr) 2000-05-19 2000-05-19 Composes neuroprotecteurs
CA2,308,994 2000-05-19
CA002409355A CA2409355A1 (fr) 2000-05-19 2001-05-18 Composes neuroprotecteurs et anti-proliferatifs
PCT/CA2001/000718 WO2001087887A2 (fr) 2000-05-19 2001-05-18 Composés neuroprotecteurs et anti-prolifératifs

Publications (1)

Publication Number Publication Date
CA2409355A1 true CA2409355A1 (fr) 2001-11-22

Family

ID=25681820

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002409355A Abandoned CA2409355A1 (fr) 2000-05-19 2001-05-18 Composes neuroprotecteurs et anti-proliferatifs

Country Status (1)

Country Link
CA (1) CA2409355A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005014584A1 (fr) * 2003-08-11 2005-02-17 Aegera Therapeutics Inc. Composes neuroprotecteurs et antiproliferatifs
CN112996521A (zh) * 2018-06-28 2021-06-18 艾升基因公司 用于诊断、治疗和预防赘生性和神经性障碍的组合物和方法

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005014584A1 (fr) * 2003-08-11 2005-02-17 Aegera Therapeutics Inc. Composes neuroprotecteurs et antiproliferatifs
GB2420780A (en) * 2003-08-11 2006-06-07 Aegera Therapeutics Inc 3-(Indol-1-yl)-4-(Indol-3-yl)-Pyrrole-2-5-Diones,3-(Benzimidazol-1-yl)-4-(Indol-3-yl)-Pyrrole-2-5-Diones, and 3-(Indolin-1-yl)-4-(Indol-3-yl)-Pyrrole-2,5-
CN112996521A (zh) * 2018-06-28 2021-06-18 艾升基因公司 用于诊断、治疗和预防赘生性和神经性障碍的组合物和方法

Similar Documents

Publication Publication Date Title
US20040102467A1 (en) Neuroprotective and anti-proliferative compounds
US6013646A (en) Indolocarbazole derivatives useful for the treatment of neurodegenerative diseases and cancer
US20240018133A1 (en) Modulators of the integrated stress pathway
US20040167199A1 (en) Methods of using and compositions comprising (-)-3-(3,4-dimethoxy-phenyl)-3-(1-oxo-1,3-dihydro-isoindol-2-yl)-propionamide
CN112204012A (zh) 整合应激通路的调节剂
CN112218869A (zh) 整合应激通路的调节剂
TW202100515A (zh) 蛋白酪胺酸磷酸酶抑制劑及其使用方法
JP2009510083A (ja) Ｎ−ベンジル置換ピリジルポルフィリン化合物およびその使用方法
KR20050012722A (ko) (+)-2-[1-(3-에톡시-4-메톡시페닐)-2-메틸설포닐에틸]-4-아세틸아미노이소인돌린-1,3-디온: 그것의 조성물 및 사용방법
WO2012003418A2 (fr) Ligands fonctionnellement sélectifs des récepteurs d2 de dopamine
EP2635575A1 (fr) Dérivés de carbazole et de carboline, et leur préparation et leurs applications thérapeutiques
EP3442592A1 (fr) Conjugués de liaison au récepteur de la neurotensine et formulations associées
WO2011008985A2 (fr) Procédés et compositions pour administration améliorée d&#39;agents thérapeutiques et de diagnostic
CN110891942B (zh) 噁二唑类衍生物、其制备方法及其在医药上的应用
US7129250B2 (en) Neuroprotective and anti-proliferative compounds
CA2409355A1 (fr) Composes neuroprotecteurs et anti-proliferatifs
AU2003294311B2 (en) Method of using and compositions comprising (+)-3-(3,4-dimethoxy-phenyl)-3-(1-oxo-1,3-dihydro-isoindol-2-yl)-propionamide

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead